ESC Premium Access

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Topic: Lipids
Sponsored by Sanofi and Regeneron

Congress Session

About the speaker

Professor Christopher Paul Cannon

Cardiovascular Division, Brigham and Women?s Hospital, Harvard Medical School, Boston (United States of America)
30 presentations
0 follower

6 more presentations in this session

LDL-C exposure and atherosclerosis progression.

Speaker: Professor A. Catapano (Milan, IT)

Thumbnail

PCSK9 inhibition: the data today and tomorrow.

Speaker: Professor S. Nicholls (Melbourne, AU)

Thumbnail

Learnings and clinical insights from SPIRE.

Speaker: Doctor P. Ridker (Boston, US)

Thumbnail

Guidelines: commonalities and discrepancies.

Speaker: Doctor J. Robinson (Iowa, US)

Thumbnail

Identifying appropriate patients to treat: a case-based approach.

Speaker: Professor C. Cannon (Boston, US) Professor A. Catapano (Milan, IT) Professor S. Nicholls (Melbourne, AU) Doctor P. Ridker (Boston, US) Doctor J. Robinson (Iowa, US)

Thumbnail

Access the full session

PSCK9 inhibition: a new horizon in LDL-C management

Speakers: Professor C. Cannon, Professor A. Catapano, Professor S. Nicholls, Doctor P. Ridker, Doctor J. Robinson...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk